Ascendis Pharma A (ASND) Other financing activities (2014 - 2026)

Ascendis Pharma A has reported Other financing activities for 13 years, with the latest figure at $37.0 million in Q1 2026.

• Quarterly Other financing activities rose 154.44% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.1 million (up 394.92% YoY) and the FY2025 annual result came in at $101.4 million, up 210.86% from the prior year.
• Other financing activities climbed to $37.0 million in Q1 2026 per ASND's latest filing, from $17.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $53.1 million in Q3 2025 and troughed at $226496.3 in Q2 2023.
• A 5-year average of $11.0 million and a median of $3.2 million in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2025: Other financing activities slumped 90.47% in 2022, then jumped 3490.58% in 2025.
• Over 5 years, Other financing activities stood at $3.2 million in 2022, then tumbled by 32.01% to $2.2 million in 2023, then jumped by 49.32% to $3.2 million in 2024, then soared by 451.16% to $17.9 million in 2025, then soared by 107.2% to $37.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $37.0 million, $17.9 million, and $53.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.